Article Figures & Data
- Table 1
Contemporary multi-institutional reports—HD IL-2 outcome
Report Response Survival Clark et al 4
RCC (2011–2015), sequenced with targeted therapy
N=352 (328 with response data)
PROCLAIM registry databaseCR 4%, PR 13%, SD 39%, PD 43%
CR+PR+SD 53%Median OS—NR for CR, PR, SD
Median OS—PD—15.5 months
PD followed by TT—med OS 29.7 months; PD no TT—med OS 8.5 months
2.5-year OS—CR 100%; PR 75%, SD 78%, PD 39%McDermott et al 5
RCC n=120
Multi-institution, prospective trialORR 25%, CR 3, PR 27
13 (11%) progression-free at 3 yearsMedian OS 42.8 months
80% TT after IL-2Alva et al 6
mM (2005–2012)—n=170
RCC (2005–2012)—n=192
Survival current 2015
PROCLAIM registry databasemM: CR 5% PR 10% SD 22%
CR+PR+SD 58% median f/u 43.1 months
RCC: CR 6%, PR 9%, SD 22%
CR+PR+SD 70% median f/u 46.6 monthsMedian OS 19.6 months
Median OS—NR for CR, PR
Median OS 33.4 months—SD
Median OS 41 months
Median OS—NR for CR, PR
Median OS 49.6 months—SDStenehjem et al 7
RCC n=391
U Utah 1988–2013
U Mich 1997–2013CR 9% PR 10%, SD 32% PD 42%
CR+PR+SD 51%Median OS CR—13+ years
Median OS PR—37.8 months
Median OS SD—34.4 monthsCR, complete response; f/u, follow-up; IL, interleukin; mM, metastatic melanoma; N, number; NR, not reached; ORR, overall response rate; OS, overall survival; PD, progressive disease; PR, partial response; RCC, renal cell carcinoma; SD, stable disease; TT, targeted therapy; U, university.
- Table 2
Patient outcomes and long-term toxicity (A) response and survival, (B) long-term toxicity
(A) Best response Metastatic melanoma Metastatic renal cell (n=54) (n=46) CR 43 38 Surgical/SRS CRs 9 5 PR
No further treatment2 3 Median follow-up 10+ years 10.5+ years Range follow-up 5+ to 15+ years 5+ to 30+ years Alive >10 years after IL-2 with no subsequent therapy 32 patients 27 patients (B) Event # Patients Hypothyroidism—requiring replacement medication (grade 2) 5 Arthralgias/Arthritis (grade 1–2) 6 Vitiligo (grade 1–2) 3 Neuropathy (grade 2) 1 Premature ventricular contractions (grade 1) 1 Normal pressure hydrocephalus (grade 1) 1 CR, complete response; DFS, disease-free survival; IL-2, interleukin-2; PR, partial response; SRS, stereotactic radiosurgery.
Supplementary Materials
Supplementary data
Additional Files
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.